Gedeon Richter Plc.

Tolebrutinib, Sanofi’s investigational treatment for non-relapsing secondary progressive multiple sclerosis (nrSPMS), is among the latest products that the European Medicines Agency has started review

Gedeon Richter championed the impact of its recent European launches of generic versions of Bayer’s Xarelto (rivaroxaban) and Boehringer Ingelheim’s Pradaxa (dabigatran), as its total Pharma revenues

Japan’s Mochida Pharmaceutical has confirmed plans to file its Gedeon Richter-partnered RGB-19 biosimilar tocilizumab candidate in Japan after achieving positive topline results from Phase I and Phase

In its latest effort to identify drugs with price increases that had the biggest impact on US health care spending, the Institute for Clinical and Economic Review (ICER) included Merck & Co.’s Key